Open AccessAxillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum
Author(s) -
Besma Musaddaq,
Adrian Brown,
Sam Dluzewski,
Teresa Marafioti,
Aseem Malhotra
Publication year - 2021
Publication title -
bjr case reports
Language(s) - English
Resource type - Journals
ISSN - 2055-7159
DOI - 10.1259/bjrcr.20210063
Subject(s) - medicine , axillary lymphadenopathy , axilla , covid-19 , vaccination , breast cancer , pandemic , disease , dermatology , surgery , pathology , infectious disease (medical specialty) , cancer
A number of COVID-19 vaccines have been approved worldwide to help tackle the pandemic. As with many vaccines, this causes a reactive axillary lymphadenopathy which can mimic potentially metastatic disease in a breast screening patient. It is therefore important to be aware of this side-effect of the vaccination when evaluating the axilla in a breast screening patient. We present a case of biopsy-proven unilateral reactive axillary lymphadenopathy in a high risk BRCA carrier following administration of the Astra Zeneca vaccine.